Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure

Critical Care Medicine

Volumn 36, Issue 1 SUPPL., 2008, Pages

  Omland, Torbjørn ^a  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

B type natriuretic peptide; Dyspnea; Heart failure; Sepsis; Shock

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; HORMONE PRECURSOR;

ACUTE HEART FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DIASTOLIC HEART FAILURE; DYSPNEA; HEART ARRHYTHMIA; HEART DISEASE; HEART HEMODYNAMICS; HEART MUSCLE ISCHEMIA; HUMAN; HYPOXIA; INTENSIVE CARE UNIT; KIDNEY FAILURE; LUNG EMBOLISM; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; REVIEW; SEPSIS; SHOCK; SYSTOLIC HEART FAILURE;

EID: 37549021468     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000296266.74913.85     Document Type: Article

References (85)

1. Nieminen MS, Bohm M, Cowie MR, et al: Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:384-416
2. Nohria A, Mielniczuk LM, Stevenson LW: Evaluation and monitoring of patients with acute heart failure syndromes. Am J Cardiol 2005; 96:32G-40G
3. Sudoh T, Kangawa K, Minamino N, et al: A new natriuretic peptide in porcine brain. Nature 1988; 332:78-81
4. Mukoyama M, Nakao K, Hosoda K, et al: Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87:1402-1412
5. Ruskoaho H: Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003; 24: 341-356
6. de Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362:316-322
7. Yandle TG, Richards AM, Gilbert A, et al: Assay of brain natriuretic peptide (BNP) in human plasma: Evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993; 76:832-838
8. Hawkridge AM, Heublein DM, Bergen HR III, et al: Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A 2005; 102: 17442-17447
9. Kinnunen P, Vuolteenaho O, Ruskoaho H: Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of stretching. Endocrinology 1993; 132:1961-1970
10. Espiner EA, Richards AM, Yandle TG, et al: Natriuretic hormones. Endocrinol Metab Clin North Am 1995; 24:481-509
11. Pemberton CJ, Johnson ML, Yandle TG, et al: Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 2000; 36:355-359
12. McCullough PA, Duc P, Omland T, et al: B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41: 571-579
13. Richards AM, Crozier IG, Yandle TG, et al: Brain natriuretic factor: Regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 1993; 69:414-417
14. Wei CM, Heublein DM, Perrella MA, et al: Natriuretic peptide system in human heart failure. Circulation 1993; 88:1004-1009
15. Omland T, Aakvaag A, Vik-Mo H: Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996; 76:232-237
16. Krishnaswamy P, Lubien E, Clopton P, et al: Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111:274-279
17. Maisel AS, McCord J, Nowak RM, et al: Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003; 41:2010-2017
18. Yamamoto K, Burnett JC Jr, Jougasaki M, et al: Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28:988-994
19. Packer M: The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20:248-254
20. Gillespie ND, McNeill G, Pringle T, et al: Cross sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnoea. BMJ 1997; 314:936-940
21. Knudsen CW, Omland T, Clopton P, et al: Diagnostic value of B-type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. Am J Med 2004; 116:363-368
22. Rihal CS, Davis KB, Kennedy JW, et al: The utility of clinical, electrocardiographic, and roentgenographic variables in the prediction of left ventricular function. Am J Cardiol 1995; 75:220-223
23. Davis M, Espiner E, Richards G, et al: Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 343:440-444
24. Maisel AS, Krishnaswamy P, Nowak RM, et al: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-167
25. McCullough PA, Nowak RM, McCord J, et al: B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106:416-422
26. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al: The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95: 948-954
27. Januzzi JL, van KR, Lainchbury J, et al: NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: An international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur Heart J 2006; 27: 330-337
28. Mueller C, Scholer A, Laule-Kilian K, et al: Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350:647-654
29. Moe GW, Howlett J, Januzzi JL, et al: N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: Primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007; 115:3103-3110
30. Tang WH, Girod JP, Lee MJ, et al: Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003; 108:2964-2966
31. Motwani JG, McAlpine H, Kennedy N, et al: Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 1993; 341:1109-1113
32. Omland T, Aakvaag A, Bonarjee VV, et al: Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996; 93: 1963-1969
33. Latour-Perez J, Coves-Orts FJ, bad-Terrado C, et al: Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: A systematic review. Eur J Heart Fail 2006; 8:390-399
34. Knebel F, Schimke I, Pliet K, et al: NT-ProBNP in acute heart failure: Correlation with invasively measured hemodynamic parameters during recompensation. J Card Fail 2005; 11(5 Suppl):S38-S41
35. Johnson W, Omland T, Hall C, et al: Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002; 39:1623-1629
36. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al: Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003; 289:194-202
37. Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al: Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: Determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006; 47: 345-353
38. Vasan RS, Benjamin EJ, Larson MG, et al: Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: The Framingham Heart Study. JAMA 2002; 288:1252-1259
39. Maisel AS, Clopton P, Krishnaswamy P, et al: Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: Results from the Breathing Not Properly (BNP) multinational study. Am Heart J 2004; 147: 1078-1084
40. McCord J, Mundy BJ, Hudson MP, et al: Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 2004; 164:2247-2252
41. Daniels LB, Clopton P, Bhalla V, et al: How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure: Results from the Breathing Not Properly multinational study. Am Heart J 2006; 151:999-1005
42. Knudsen CW, Omland T, Clopton P, et al: Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: An analysis from the breathing not properly multinational study. J Am Coll Cardiol 2005; 46: 838-844
43. Knudsen CW, Clopton P, Westheim A, et al: Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: An analysis from the breathing not properly multinational study. Ann Emerg Med 2005; 45:573-580
44. van Kimmenade RR, Pinto YM, Bayes-Genis A, et al: Usefulness of intermediate aminoterminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol 2006; 98: 386-390
45. Anand IS, Fisher LD, Chiang YT, et al: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1278-1283
46. Bettencourt P, Azevedo A, Pimenta J, et al: N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110: 2168-2174
47. Cheng V, Kazanagra R, Garcia A, et al: A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study. J Am Coll Cardiol 2001; 37:386-391
48. Harrison A, Morrison LK, Krishnaswamy P, et al: B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002; 39:131-138
49. Januzzi JL Jr, Sakhuja R, O'Donoghue M, et al: Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 2006; 166:315-320
50. Maisel A, Hollander JE, Guss D. et al: Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004; 44:1328-1333
51. Wu AH, Smith A: Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 2004; 6:355-358
52. Araujo JP, Azevedo A, Lourenco P, et al: Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure. Am J Cardiol 2006; 98:1248-1250
53. Stevenson LW: Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail 1999; 1:251-257
54. Stevenson LW, Maisel AS: Clinical use of natriuretic peptides in the diagnosis and management of heart failure. In: Cardiovascular Biomarkers: Pathophysiology and Disease Management. Morrow DA (Ed). Totowa, NJ, Humana Press, 2006, pp 387-408
55. McLean AS, Huang SJ, Nalos M, et al: The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients. Crit Care Med 2003; 31:2611-2618
56. Charpentier J, Luyt CE, Fulla Y, et al: Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004; 32:660-665
57. Connors AF Jr, Speroff T, Dawson NV, et al: The effectiveness of right heart catheterization in the initial care of critically ill patients: SUPPORT investigators. JAMA 1996; 276:889-897
58. Sandham JD, Hull RD, Brant RF, et al: A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003; 348:5-14
59. Maeder M, Fehr T, Rickli H, et al: Sepsis-associated myocardial dysfunction: Diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 2006; 129:1349-1366
60. Witthaut R, Busch C, Fraunberger P, et al: Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: Impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 2003; 29:1696-1702
61. Forfia PR, Watkins SP, Rame JE, et al: Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol 2005; 45:1667-1671
62. Tung RH, Garcia C, Morss AM, et al: Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Crit Care Med 2004; 32:1643-1647
63. Rudiger A, Gasser S, Fischler M, et al: Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 2006; 34:2140-2144
64. Januzzi JL, Morss A, Tung R, et al: Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: A prospective cohort study. Crit Care 2006; 10:R37
65. Roch A, Lardet-Servent J, Michelet P, et al: NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 2005; 33:1001-1007
66. Cuthbertson BH, Patel RR, Croal BL, et al: B-type natriuretic peptide and the prediction of outcome in patients admitted to intensive care. Anaesthesia 2005; 60:16-21
67. McCullough PA, Hollander JE, Nowak RM, et al: Uncovering heart failure in patients with a history of pulmonary disease: Rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 2003; 10:198-204
68. Jefic D, Lee JW, Jefic D, et al: Utility of B-type natriuretic peptide and N-terminal pro Btype natriuretic peptide in evaluation of respiratory failure in critically ill patients. Chest 2005; 128:288-295
69. Vieillard-Baron A, Schmitt JM, Augarde R, et al: Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: Incidence, clinical implications, and prognosis. Crit Care Med 2001; 29: 1551-1555
70. Mitaka C, Hirata Y, Nagura T, et al: Increased plasma concentrations of brain natriuretic peptide in patients with acute lung injury. J Crit Care 1997; 12:66-71
71. Grasso S, Leone A, De MM, et al: Use of N-terminal pro-brain natriuretic peptide to detect acute cardiac dysfunction during weaning failure in difficult-to-wean patients with chronic obstructive pulmonary disease. Crit Care Med 2007; 35:96-105
72. Nagaya N, Nishikimi T, Uematsu M, et al: Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870
73. Reynolds EW, Ellington JG, Vranicar M, et al: Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 2004; 114:1297-1304
74. Kruger S, Graf J, Merx MW, et al: Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J 2004; 147:60-65
75. Book WM, Hott BJ, McConnell M: B-type natriuretic peptide levels in adults with congenital heart disease and right ventricular failure. Am J Cardiol 2005; 95:545-546
76. Nagaya N, Ando M, Oya H, et al: Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy. Ann Thorac Surg 2002; 74:180-184
77. Kucher N, Printzen G, Goldhaber SZ: Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003; 107:2545-2547
78. Kucher N, Printzen G, Doernhoefer T, et al: Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003; 107: 1576-1578
79. ten WM, Tulevski II, Mulder JW, et al: Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 2003; 107: 2082-2084
80. Phua J, Lim TK, Lee KH: B-type natriuretic peptide: issues for the intensivist and pulmonologist. Crit Care Med 2005; 33: 2094-2013
81. McCullough PA, Sandberg KR: B-type natriuretic peptide and renal disease. Heart Fail Rev 2003; 8:355-358
82. van Kimmenade RR, Januzzi JL Jr, Baggish AL, et al: Amino-terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure: Redefining the cardiorenal interaction? J Am Coll Cardiol 2006; 48:1621-1627
83. Etgen T, Baum H, Sander K, et al: Cardiac troponins and N-terminal pro-brain natriuretic peptide in acute ischemic stroke do not relate to clinical prognosis. Stroke 2005; 36:270-275
84. Berendes E, Walter M, Cullen P, et al: Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet 1997; 349:245-249
85. Tung PP, Olmsted E, Kopelnik A, et al: Plasma B-type natriuretic peptide levels are associated with early cardiac dysfunction after subarachnoid hemorrhage. Stroke 2005; 36:1567-1569